Zacks Investment Research on MSN3d
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago. These ...
ETF Daily News6d
Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Monday
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses ...
pharmaphorum5mon
Ipsen crosses EU finish line with Alagille syndrome drug
is labelled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow – in children aged six months and over with ALGS, a disease caused by a genetic mutation ...
Nasdaq3mon
Aligos Therapeutics, Inc. Common Stock (ALGS) Institutional Holdings
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...